Supply Chain

Ruth Beadle, head, global supply chain, Sanofi, discusses the company’s multi-year effort to build an AI-powered, end-to-end supply chain focused on improving service, resilience, and cost efficiency.

Ruth Beadle, head, global supply chain, Sanofi, explains how the company balances daily operations with long-term transformation efforts to ensure timely delivery of critical medications to patients.

Trump anticipates that the executive order will help lower drug prices by 30% to 80%.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, discusses the obstacles in documenting and proving DSCSA compliance.

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

The President plans to sign an executive order on Monday morning to enforce the trade clause.

In the third part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, shares the challenges that stakeholders are encountering, along with a possible change to the national drug code that could be on the way.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

In the second part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, comments on stakeholders’ overall preparedness for complying with the latest enforcement deadlines.

The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.

In the first part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, shares his overall thoughts on this year’s DMC.

The move bolsters the CDMO’s commitment to cell and gene therapy by incorporating advanced manufacturing and fill-finish capabilities.

As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders become more prevalent, self-injectables are here to stay.

The Zensights Federated Healthcare Advisory Panel explores how shifting global dynamics are reshaping access and strategic planning across the healthcare system.

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes potential availability challenges brought on by supply chain obstacles.

The program measures a company’s air cargo supply chain efforts when it comes to quality, safety, and compliance.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, comments on the steps needed to achieve Drug Supply Chain Security Act compliance.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, describes his day-to-day workflow at Morris & Dickson, and how it supports the efficiency and reliability of the distributor’s operations.